A survey of UK centres on low iodine diet recommendations prior to radioiodine ablation therapy for differentiated thyroid cancer by England, C. Y. et al.
                          England, C. Y., Moss, L., Beasley, M., Haupt-Schott, I., Herbert, G., &
Atkinson, C. (2019). A survey of UK centres on low iodine diet
recommendations prior to radioiodine ablation therapy for differentiated
thyroid cancer. European Thyroid Journal.
https://doi.org/10.1159/000504706
Peer reviewed version
Link to published version (if available):
10.1159/000504706
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via Karger Publishers at https://www.karger.com/Article/Abstract/504706 . Please refer to any applicable terms
of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/user-
guides/explore-bristol-research/ebr-terms/
 1 
 
A survey of UK centres on low iodine diet recommendations prior to radioiodine ablation therapy 
for differentiated thyroid cancer 
Clare Yvonne England1,2*, Laura Moss3, Matthew Beasley4, Ingrid Haupt-Schott3, Georgia Herbert1, 
Charlotte Atkinson1 
1National Institute for Health Research Bristol Biomedical Research Centre, University Hospitals 
Bristol NHS Foundation Trust and University of Bristol, Bristol, UK 
2Centre for Exercise Nutrition and Health Sciences, School for Policy Studies, University of Bristol, 
Bristol, UK 
3Velindre Cancer Centre, Velindre Road, Whitchurch, Cardiff, UK 
4University Hospitals Bristol NHS Trust, Marlborough Street, Bristol, UK 
 
Running title: Low iodine diet 2019 survey 
 
Corresponding author 
Clare Yvonne England 
Centre for Exercise, Nutrition and Health Science, School for Policy Studies, University of Bristol 
8 Priory Road 
Bristol 
Tel: 0117 342 1759 or 0117 331 0573 
e-mail: clare.england@bristol.ac.uk 
 
Keywords: Thyroid cancer; low iodine diet; radioiodine ablation; survey 
 
 2 
 
Abstract 
Background: Guidelines suggest that a low iodine diet (LID) is advised prior to radioiodine ablation 
(RIA) for thyroid cancer. We aim to describe current practice regarding LID advice in the UK, determine 
uptake of the 2016 UK LID Working Group diet sheet and discover whether there are differences in 
practice. Methods: Online survey distributed between November 2018-April 2019 to centres in the 
UK that administer 131I. We asked questions on whether a LID is advised, for how long, how advice is 
presented, whether and how compliance is measured and whether treatment is delayed if LID advice 
is not followed. Results: Fifty-six clinicians from 47 centres that carry out RIA for thyroid cancer 
responded. Forty-four centres (94%) advise a LID prior to RIA, the majority for 14 days (82%). Two-
thirds of centres use the UK LID Working Group diet sheet. Patients are told to resume normal eating 
when 131I is administered at 17 (39%) centres, with 18 (41%) advising waiting for 24-48 hours after 
administration. Most centres (95%) use only a simple question or do not assess compliance. Only 2 
(5%) indicate that RIA would be delayed if someone said they had not followed LID advice. 
Conclusions: UK practice regarding the LID prior to RIA for thyroid cancer is consistent with current 
guidelines but non-adherence does not usually delay RIA. The UK Low Iodine Diet Working Group diet 
sheet is widely recognised and used. Practice could be improved by centres working to harmonise 
advice on when to restart a normal diet. 
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Background 1 
Thyroid cancer accounts for less than 1% of cancer cases in the UK. However, incidence is increasing 2 
and between 2014 to 2016 there were an average of 3527 new cases of thyroid cancer annually in the 3 
UK, compared to 1125 in 1993(1, 2). Differentiated thyroid cancer accounts for 95% of cases. The 4 
prognosis for differentiated thyroid cancer is good, 10-year survival rate is 80-90%, although 5 
recurrence or persistent disease is estimated to occur in 10-30% of cases(3), with rates as high as 68% 6 
observed in high risk patients(4). Treatment is often total thyroidectomy, followed by radioiodine 7 
remnant ablation with 131I (RIA) to destroy thyroid tissue remaining post-surgery(5). High iodine status 8 
can interfere with uptake of 131I. The UK Guidelines for the management of thyroid cancer state that, 9 
based on expert opinion, exposure to iodinated contrast and treatment with drugs or supplements 10 
high in iodine should be avoided, and people should be advised to follow a low iodine diet (LID) of 1-11 
2 weeks, prior to RIA(5). There is, however, mixed evidence on whether LIDs impact on ablation 12 
success(6), particularly in countries with generally low iodine intakes such as the UK(7). 13 
Two reviews have been conducted, one systematic(8), one narrative(6), examining the use of LIDs 14 
prior to RIA. Randomised controlled trials indicate that advice to follow a LID for 1-2 weeks reduces 15 
urinary iodine. However, evidence that LID advice improves ablation success comes only from 16 
retrospective studies and is inconclusive. A study in the Netherlands(9) compared people who 17 
followed a LID for 7-days and reduced  24-hour urinary iodine excretion to <50mcg/day with historic 18 
controls given no dietary advice. Those following a LID experienced 65% success rate vs 48% for 19 
controls (p<0.001). A study in Korea(10) found only excessive iodine intake, measured as a urinary 20 
iodine creatinine ratio (UI/Cr) >250mcg/gCr, to be associated with increased odds of  unsuccessful 21 
ablation (OR: 4.74, 95% CI: 1.78–12.63). Three other retrospective studies, in the USA(11) and 22 
Korea(12, 13) have found no difference in ablation success rates between cohorts that were advised 23 
a 10-14 day LID and historic controls who were given no advice(11); no difference between people 24 
following a very restrictive 2-week LID vs those following a less restrictive 2-week LID(12); and no 25 
difference in either ablation success or spot urine iodine concentration (UIC) between people 26 
following a 1-week vs those following a 2-week LID(13). 27 
Despite the mixed evidence, the European Association of Nuclear Medicine Therapy Committee 28 
recommends that RIA should be postponed if UIC is >150-200mcg/l(3) and that clinicians should aim 29 
for a UIC <100mcg/l or a UI/Cr of <100mcg/gCr, with optional LID advice. UK guidelines do not give 30 
details on the level of iodine restriction necessary to achieve a UI/Cr of <100mcg/gCr, whereas 31 
American Thyroid Association guidelines advise restricting iodine intake to <50mcg/day(6). In 32 
contrast, in Korea, where intakes of iodine are much higher than in the UK and USA, guidelines are to 33 
restrict iodine intake to <100mcg/d. Italian guidelines do not advise an LID at all prior to RIA(14). 34 
In the 2000s, there were anecdotal reports in the UK that there were variations in practice and patients 35 
were finding LID advice confusing(15). Consequently, the UK Low Iodine Diet Working Group (UK LID-36 
WG) developed a UK LID diet sheet(16) and initially distributed it in 2016  (supplement). It is uncertain 37 
how widespread use of the diet sheet is and, given the lack of robust evidence that a LID affects 38 
ablation success and that international guidelines differ, it is possible that practice within the UK still 39 
varies. 40 
This study was a survey of current practice regarding advice on LIDs prior to RIA in the UK. The aims 41 
were to determine whether practice varies across different centres, whether the UK LID-WG diet sheet 42 
is in use (and if not, why not) and to discover whether centres monitor compliance with a LID and if 43 
treatment is delayed if a LID is not followed. 44 
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Methods 45 
A short electronic survey was designed on Online Surveys (Jisc, UK) for distribution to centres in the 46 
UK that administer 131I for people undergoing treatment for thyroid cancer. The survey included 10 47 
main questions, with a maximum of 20 follow-ups. Questions were a mixture of multiple choice with 48 
some free text boxes and included questions on how well clinicians thought patients coped with the 49 
diet (supplement). The survey could be completed anonymously, although at the end people were 50 
asked to identify their centre. Participation in the survey was voluntary, with informed consent 51 
assumed through completion. 52 
There is no national list of centres that administer radioiodine in the UK. A list of possible centres was 53 
created from information held by the UK LID-WG, the Internal Dosimetry Users Group and through 54 
the authors’ clinical networks. A brief invitation e-mail containing a link to the questionnaire and an 55 
explanation of the purpose of the survey was sent to identified centres in November 2018 and up to 56 
three reminders were sent between January 2019-April 2019. Practice regarding who prescribes and 57 
administers RIA varies in the UK, so e-mail addresses of clinicians known personally to the authors or 58 
listed on hospital websites were used or e-mails were sent to Nuclear Medicine or radiology 59 
department addresses. The e-mail included the contact details of two of the authors (CE and LM) so 60 
that recipients could find out more details or request no further contact. Information and a link to the 61 
survey was also distributed at a Thyroid Cancer Study day held at the Royal Marsden Hospital, London 62 
in December 2018. In April 2019 follow up e-mails were sent to hospitals in regions that appeared to 63 
have low coverage. 64 
Responses were collated and are presented descriptively. Qualitative free text responses were 65 
summarised. 66 
Results 67 
Sixty-four hospitals were contacted, and responses were received from 53 (83%). Six hospitals (9%) 68 
indicated that they were not centres for RIA for thyroid cancer. Clinicians from 47 centres 69 
administering RIA (73%) completed the survey. For seven centres two responses were received and 70 
for one centre there were three responses, giving a total of 56 responses. Overall, national coverage 71 
was good (table 1). Responses were received from radiologists and nuclear medicine specialists  72 
(physicists and nurses) (n=15),  other clinical nurse specialists (n=12), clinical scientists (n=12), 73 
oncologists (n=8), nuclear medicine consultants (n=3), unspecified consultants (n=4), one 74 
endocrinologist and one dietitian. 75 
The mean estimated number of people treated with radioiodine for thyroid cancer at each centre/year 76 
was 46 (SD 28), giving a total estimated number of people treated of 2182 annually. The minimum 77 
number treated per centre was estimated to be 10 people, the maximum 150. 78 
Three centres did not routinely advise a LID prior to RIA for all people. Of these, one small centre 79 
(treating approximately 10 people/year) indicated that they were not aware of the guidelines and 80 
another (treating approximately 80 people/year) indicated that there was no evidence for 81 
effectiveness. The remaining centre (treating approximately 40 people/year) responded that the 82 
provision of LID advice varied by clinician and it was more common not to advise the diet. Another 83 
centre also indicated that advice to follow a LID varied by clinician, one centre advised a LID for only 84 
2 days prior to RIA, all others advised restriction for 1-2 weeks, as per the guidelines.  85 
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Table 2 summarises survey answers from the 44 centres who indicated that they advised people to 86 
follow a LID. For some questionnaire items, different responses were provided by different clinicians 87 
from the same centre, indicated in the table. 88 
Most centres (66%) reported using the UK LID-WG diet sheet. Of those who did not, four (9%) were 89 
not aware of the working group suggestions and clinicians from four centres (9%) thought it was too 90 
restrictive, one of whom specifically said they did not advise people to restrict dairy products as much. 91 
People were instructed to resume a normal diet immediately after taking 131I at 17 (39%) centres, 2 92 
hours after taking the RIA capsule by one centre and 24-48 hours after taking the capsule at 18 (41%) 93 
centres. Six centres indicated that people were instructed to resume a normal diet 24-48 hours after 94 
treatment, but a LID inpatient menu was not provided. Compliance with the LID advice was assessed 95 
in 26 (59%) centres, although all except one used a simple verbal check rather than a formal dietary 96 
assessment. None of the centres reported measuring iodine status and only two clinicians said their 97 
centre would delay treatment if someone said they had not followed a LID. 98 
Thirty-one of the 56 clinicians (53%) indicated that they thought people coped very well with the diet, 99 
although free text comments indicated that some groups of people were more likely to find the diet 100 
difficult, specifically, people with diabetes, vegans/vegetarians, older people and people from non-101 
British backgrounds. The diet was identified as being a source of anxiety for some people, and there 102 
were comments that some people were more restrictive than advised and attempted to follow no-103 
iodine diets, rather than reduced iodine. However, clinicians also said that there were people who 104 
liked feeling in control of a part of their cancer treatment, and who experienced other health benefits 105 
from thinking about what they were eating. The UK LID-WG diet sheet was highlighted as making 106 
advice clearer and easier to follow. 107 
Two clinicians (a clinical nurse specialist and an oncologist) thought that people did not cope with the 108 
diet but provided no specific comments, and one oncologist reported not asking about the diet 109 
because they didn’t think there was good evidence for efficacy so it didn’t matter if people followed 110 
it or not. 111 
Discussion 112 
This study gives information about clinical practice regarding low iodine diets prior to RIA for thyroid 113 
cancer in the UK since the introduction of the UK LID-WG diet sheet(16). The response rate was good 114 
with very good coverage across the regions of the UK, including all the devolved nations. Most centres 115 
advise a 14-day LID but there were variations regarding the advice given between centres. Overall, 116 
there was good awareness and usage of the UK LID-WG diet sheet and only four centres indicated that 117 
they were unaware of it. A further four said that they disagreed with some of the information in the 118 
sheet.  119 
Variations in practice are perhaps unsurprising given the lack of clear evidence that following a LID or 120 
reducing UIC improves ablation success(6, 8). Of the four centres that reported not routinely advising 121 
a LID, only one large centre explicitly stated that they did not think the evidence was good enough. 122 
However, adherence to the diet was either not assessed at all or assessed by a simple question by 123 
most clinicians and only two indicated that treatment would be delayed if people reported that they 124 
did not follow a LID. This may reflect either a widespread lack of belief that the diet is necessary, as 125 
stated by one clinician, or a lack of confidence in ability to assess diet. None of the centres assessed 126 
iodine status using urinary iodine measurements, again perhaps unsurprising given concerns over 127 
inaccuracies in determining iodine status from UIC(17). 128 
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There appears to be most disagreement in practice about when people should restart a normal diet 129 
following RIA. Twenty-five of the 56 clinicians who answered the survey reported that they advised 130 
people to continue with dietary restriction 24-48 hours after RIA and six indicated that the LID was 131 
stopped after post-therapy whole body scan (Px-WBS), presumably to ensure good uptake of 131I. 132 
Although we did not ask each centre to report when the Px-WBS occurred, it is carried out when 133 
residual activity permits imaging, typically around 2-10 days after RIA(5). Studies that examine 134 
whether advice to follow a LID improves ablation success report asking people to follow a LID prior to 135 
RIA but did not appear to ask people to continue after 131I has been administered(9-11, 13), unless a 136 
Px-WBS was carried out(12). To our knowledge, no studies have assessed whether continuing a LID 137 
beyond the administration of RIA confers any benefit on outcomes, or what effect resuming a usual 138 
diet has on iodine status in this immediate post-treatment period. 139 
As a survey of practice, our study did not capture what patients think of the LID. Over half of clinicians 140 
(53%) indicated that people coped very well with the diet, although some suggested that there are 141 
groups of people who struggle and that some people attempt to follow a very restrictive no-iodine 142 
diet. Two studies, both conducted in Korea, reported that people believed the LID to be important but 143 
found it difficult to follow because they enjoyed foods high in iodine, struggled to find alternatives 144 
and found it difficult to eat outside the home(18, 19). Difficulties with food eaten outside of the home 145 
were also reported by people in Brazil(20). Experiences may be different in the UK since the typical 146 
Korean diet is very high in iodine(21) and, in Brazil salt is iodized(20). However, there was anecdotal 147 
evidence that people in the UK found LID advice confusing and difficult to follow before the UK LID-148 
WG released the standardised diet sheet(15). Clinicians in the current survey indicated that the 149 
standardised diet sheet has improved advice, but questions from people about the LID are still 150 
frequently posted on on-line forums(22).This is perhaps because there is potential for confusion if 151 
people find on-line advice from countries where salt is iodized (e.g., the USA) unlike the UK.  152 
This study is the most comprehensive overview of UK practice regarding advice on the LID prior to RIA 153 
for thyroid cancer to date but there are some limitations. Despite good coverage, it is likely that not 154 
all UK centres have taken part. It is also possible that the clinician who completed the survey may not 155 
have been the one who knew most about practice regarding the LID in their centre, despite the initial 156 
recipient being asked to forward it to a more appropriate person if they felt they were unable to 157 
answer the questions. Overall, however, we are confident that this study is broadly representative of 158 
current UK practice regarding LID advice prior to RIA therapy for thyroid cancer. 159 
We found evidence that the UK LID-WG diet sheet is recognised, used and has improved practice. 160 
Most UK practice regarding the LID is in line with current guidelines but there are variations between 161 
centres and non-adherence to the diet does not usually delay RIA. This is, perhaps, due to lack of 162 
convincing evidence in the literature that the LID is necessary. There is a need for more research in 163 
this area and this study is a part of an ongoing work investigating the LID. We are currently conducting 164 
a multi-centre retrospective review of ablation success rates between UK centres giving different LID 165 
advice, a qualitative study exploring patient experiences with the LID and a mixed- methods review of 166 
the literature regarding the LID prior to RIA for thyroid cancer. However, since LID advice is widely 167 
given at present, UK practice could be improved with more detailed assessment of dietary compliance, 168 
and harmonisation of advice on when to restart a normal diet. 169 
2491 words 170 
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